Trogenix (NASDAQ: TROG) Reports Breakthrough Pre-Clinical Results in Brain Cancer Model
Key Developments Trogenix (NASDAQ: TROG) has unveiled groundbreaking pre-clinical findings published in Nature, showcasing complete tumour eradication and sustained protective effects in an advanced brain cancer model reflecting human glioblastoma. This development highlights Trogenix’s innovative cancer immunotherapy approach aimed at delivering long-lasting remission against one of the deadliest brain tumours. The reported data marks a pivotal advancement as Trogenix progresses towards clinical application, with plans to initiate patient dosing in…
